+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatitis B vaccination in patients infected with Schistosoma mansoni: duration of immunity and immunogenicity of a low dose intradermal booster



Hepatitis B vaccination in patients infected with Schistosoma mansoni: duration of immunity and immunogenicity of a low dose intradermal booster



Transactions of the Royal Society of Tropical Medicine and Hygiene 84(3): 401-402



The immune response of 16 individuals with hepatosplenic schistosomiasis, who were vaccinated against hepatitis B, was followed up 4-5 years after vaccination. A protective level of antibody to hepatitis B surface antigen (HBsAg) persisted in 8 of 13 patients; 3 patients who had not responded originally, remained antibody-negative. Twelve of the 16 patients were re-vaccinated with a single booster dose. Six of the 7 subjects whose antibody levels had remained protective, and 3 of 5 whose levels were <10 mIU/ml, responded well to the booster dose. Both patients who failed to develop antibody after the booster had massive splenomegaly. As schistosomiasis and hepatitis B are both potential causes of liver damage in Egypt, prevention of the latter disease by vaccination is desirable in the presence of the former. Anti-hepatitis antibodies persisted 4-5 years in 8 (62%) of 13 patients vaccinated with a standard 3-dose subcutaneous regimen. An intradermal booster (1 in 10 dose) was successful although 20% achieved antibody levels <100 miu/ml only. Previous non-responders failed also with this booster. These latter patients had severe hepatic fibrosis-the ones who most needed protection..G. Brook.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 001850683

Download citation: RISBibTeXText

PMID: 2148039

DOI: 10.1016/0035-9203(90)90336-d


Related references

Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Annals of Internal Medicine 108(2): 185-189, 1988

Immunogenicity of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 641A, 2001

Immunogenicity of hepatitis B vaccine in patients infected with Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene 36(3): 549-553, 1987

Safety and immunogenicity of a recombinant hepatitis B vaccine in patients infected with Schistosoma mansoni. American Journal of Tropical Medicine and Hygiene 42(5): 449-452, 1990

Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination. Perspectives in Clinical Research 5(3): 134-138, 2014

Persistence of antibody and response to a booster with low dose intradermal hepatitis b vaccination. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 31: 283, 1991

Duration of response to intramuscular versus low dose intradermal hepatitis B booster immunization. Infection Control and Hospital Epidemiology 12(4): 226-230, 1991

Intradermal hepatitis B vaccination: efficacy and timing for a booster dose in infants at risk. Pediatric Infectious Disease Journal 8(5): 337, 1989

Immunogenicity of low dose intradermal hepatitis B vaccine and its comparison with standard dose intramuscular vaccination. Indian Pediatrics 41(9): 922-926, 2004

Immunogenicity of low-dose intramuscular and intradermal vaccination with recombinant hepatitis B vaccine. Revista do Instituto de Medicina Tropical de Sao Paulo 39(1): 15-19, 1997

Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. Journal of Infectious Diseases 200(6): 935-946, 2009

Low dose 2 microgram hepatitis b vaccination in medical students comparable immunogenicity for intramuscular and intradermal routes. Journal of Medical Virology 27(2): 151-154, 1989

Hepatitis B vaccination in children infected with Schistosoma mansoni: correlation with ultrasonographic data. American Journal of Tropical Medicine and Hygiene 43(5): 516-519, 1990

Low dose intradermal vaccination is superior to high dose intramuscular vaccination for hepatitis B in unresponsive hemodialysis patients. Renal Failure 29(3): 285-288, 2007

Immune response of intradermal hepatitis B vaccination at lower dose versus intramuscular vaccination at double standard dose in predialytic chronic renal failure patients. Journal of the Medical Association of Thailand 86(12): 1122-1127, 2003